New Delhi: The Roche Group on Wednesday said that a clinical trial of its patented drug tocilizumab did not meet its primary and secondary endpoints, respectively, of improving clinical status of patients with covid-19 associated pneumonia and reducing patient mortality.The study, called COVACTA, is the first global, randomised, double-blind, placebo-controlled phase III trial of the drug.
The study on 450 patients across 67 sites in the US was conducted by the company in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), an agency in the US Department of Health and Human Services.“People around the world are waiting for further effective treatment options for COVID-19 and we are disappointed that COVACTA.